613 results on '"Cid, Maria C"'
Search Results
2. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
3. Cranial involvement in giant cell arteritis
4. Decoding CD4+ T cell transcriptome in giant cell arteritis: Novel pathways and altered cross-talk with monocytes
5. Maternal and fetal outcomes of pregnancy in women with primary systemic vasculitis: A single-center cohort study of 20 patients and 30 pregnancies
6. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
7. Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis
8. Single-cell transcriptomic profiling reveals a pathogenic role of cytotoxic CD4+ T cells in giant cell arteritis
9. Polymyalgia rheumatica
10. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
11. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis
12. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
13. Hybrid 18F-FDG-PET with CT angiography for diagnosis of Takayasu arteritis
14. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
15. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
16. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.
17. The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases
18. Large-vessel vasculitis
19. Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
20. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
21. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
22. Re: Nair et al. Consensus statement on the processing, interpretation and reporting of temporal artery biopsy for arteritis
23. Biological treatments in giant cell arteritis & Takayasu arteritis
24. B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Kill Pathological Vessels?
25. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis
26. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma
27. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
28. B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?
29. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
30. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
31. Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
32. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
33. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study
34. Susac Syndrome: Description of a Single-Centre Case Series
35. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma
36. Hybrid 18F-FDG-PET with CT angiography for diagnosis of Takayasu arteritis.
37. The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
38. Polyarteritis Nodosa
39. Factors related to glucocorticoid-induced osteoporosis and fragility fractures in young subjects
40. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
41. Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis
42. The cryoglobulinaemias
43. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
44. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
45. Large-vessel vasculitis
46. Aetiology and pathogenesis
47. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
48. The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
49. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
50. Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.